Aldeyra Therapeutics (ALDX) Proxy filing summary

Executive summary

• The annual meeting is scheduled for June 9, 2026, with voting available online, by phone, or mail for shareholders of record as of April 13, 2026.

• Proxy materials include the proxy statement, annual report on Form 10-K for 2025, and voting instructions.

• The board encourages shareholder engagement and provides multiple channels for communication and proposal submissions.

Voting matters and shareholder proposals

• Shareholders will vote on electing one Class III director, ratifying the appointment of BDO USA, P.C. as auditor for 2026, and a non-binding advisory vote on executive compensation.

• The board recommends voting FOR all proposals; broker discretionary voting is only allowed for auditor ratification.

• Shareholder proposals for the 2027 meeting must be submitted by December 28, 2026, for proxy inclusion.

Board of directors and corporate governance

• The board consists of eight members divided into three staggered classes; all but the CEO are independent per Nasdaq rules.

• Board committees include audit, compensation, nominating/corporate governance, and stock option committees, each with defined charters and independence requirements.

• The board separates the roles of CEO and chair, with regular executive sessions for independent directors.

• Director candidates are evaluated for expertise, diversity, independence, and commitment to shareholder interests.